10.3390/agriculture2040452 [DOI] [Google Scholar] Villeneuve D
Weight loss injections primarily refer to glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications originally developed for type 2 diabetes management but now FDA-approved for chronic weight management in adults with BMI 30 kg/m (or 27 kg/m with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia)
Theaflavin protects against oxalate calcium-induced kidney oxidative stress injury via upregulation of SIRT1
MUC1 directly binds to the intracellular domain of CD44, which further stabilizes the expression levels of SLC7A11 (7,46)
These signaling pathways converge further, through the regulation of Forkhead box class O (FoxO) transcription factors
A minimum 4-month rest period follows each cycle, with a maximum of 3 cycles per year